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Engineered In Vitro Breast Cancer Models Show Phenotypic Differentiation 
Characteristics of Early vs. Late-Stage Disease 
Harini Venkata Krishnan, B.Tech 
University of Pittsburgh, 2016 
Cancer drug discovery and development is challenged by poor prediction of drug responses in 
in vitro disease models. Results from clinical trials suggest that just 5% of drugs tested are 
successful in patients. Currently used disease models such as two-dimensional (2D) cell 
monolayers and in vivo animal models fail to recapitulate the human tumor microenvironment. 
Further, disease progression from the non-invasive to metastatic stage needs models that can 
recapitulate each stage. Hence, there is an unmet need to develop three-dimensional (3D) 
models that capture natural tumor progression for better understanding of disease biology as 
well as screening of drug regimens acting on different disease stages.  
In this work, we have characterized 3D breast microtumors ranging from 150 to 600 μm 
diameters using non-invasive T47D cells with precise control over physicochemical 
microenvironmental factors. In this study, we test the hypothesis that the size-controlled 
microtumors will exhibit differential biochemical features and drug response arising from unique 
molecular signatures created by variable tumor microenvironments. To test this hypothesis, we 
studied the physicochemical features such as hypoxia, reactive oxygen species, metabolic 
activity, and cell cycle status. Additionally, the expression of key regulators of 
growth/proliferation pathways in breast cancer progression such as estrogen receptor alpha 
(ER-α) and growth factor receptor/s was studied and efficacy of clinically used inhibitors such as 
4-hydroxytamoxifen (4-OHT) was evaluated.  
The results indicated that large T47D microtumors (600 μm) exhibited traits of clinically 
advanced tumors such as collective cell migration, mesenchymal marker upregulation, loss of 
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ER-α and endocrine resistance in contrast to the small microtumors (150 μm). Thus, the 
engineered in vitro models could successfully recapitulate phenotypic differentiation 
characteristics of early vs. late disease stage in the same non-invasive T47D cells just by 
precisely controlling the microtumor size, which further regulated the tumor microenvironmental 
factors. The large microtumors (600 μm) were found to resemble features of advanced stage 
breast cancer whereas the small microtumors (150 μm) recapitulated features of early stage 
breast cancer. Hence, such disease stage-specific microtumor models could help in the 
evaluation of crucial mechanisms in breast tumor progression correlated to tumor size and in 
the screening of therapeutic candidate/s. 
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1.  INTRODUCTION 
 
3D cell culture models in cancer 
Development of anti-cancer drugs has been a challenging issue for the medical and 
pharmaceutical fraternity. Cell culture studies are an integral part of drug discovery and 
development as well as cancer biology studies. Traditionally, cells have been grown as 
monolayers on flat surfaces like petri plates or tissue culture flasks. However, it was realized 
that tissues and organs in vivo possessed 3D structure that enabled cell-cell and cell-matrix 
interactions [2]. Thus, over the past two decades many researchers have tried designing 3D 
models to reliably resemble the native tissue environment [3]. The two main categories of 3D 
models for cancer discovery are listed below. 
 
Spheroids 
Spheroids are multicellular aggregates that mimic natural tumors. They consist of only one or 
more kind of cells (tumor cell, stem cell, fibroblasts, etc.) isolated from specific cell lines. 
Alternatively, they can be fragments of the cancerous tissue/organ. They are spontaneously 
formed when cell-cell interactions overweigh cellular interactions with other entities (ECM, 
hormones, endogenous ligands, etc.) [4]. 
The multicellular architecture of spheroids mimics solid tumors in vivo. They are typically formed 
in the size range of 100 to 200 microns in diameter [5]. 3D multicellular structure causes 
diffusion limitation for oxygen and nutrients resulting in differential zones of proliferating and 
non-proliferating cells inside the spheroid. This simulates the metabolic profile generally 
observed naturally during tumor progression in vivo [6].     
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Spheroids can be produced by many techniques either in a suspension or gel embedded 
system. The hanging drop technique is one of the oldest methods which consist of cells inside a 
droplet of culture medium suspended on the underside of a culture dish [7]. Other methods for 
generating spheroids include growing cells in non-adherent surfaces such as agar, basement 
membrane, etc. The non-adherent surface enables cells to move towards each other and form 
aggregates [5].     
Alternative methods for spheroid generation involve continuous agitation of culture suspension 
inside spinning flasks and NASA rotary vessels that avoid cells from settling down [8]. These 
methods are preferred for large scale production. However, these agitation techniques require 
special equipment and produce non-uniform spheroids. This non-uniformity makes spheroid 
production less reproducible. Advances in microfabrication technology have led to the formation 
of spheroids inside microwell arrays [9]. While some groups use photolithography to imprint 
micrometer size wells on non-adhesive polymer surfaces, others have scaled up this technique 
to 96 well plate [10]. 
Additionally, spheroids have been embedded inside gels made up of collagen, Matrigel and 
polyethylene glycol (PEG) [8]. Such encapsulation provides for interactions between cells and 
ECM. Further, some researchers have developed heterogeneous spheroids in these gels by co-
culturing two types of cells like fibroblasts and epithelial cells [11].  
 
Scaffolds 
Tissue engineering has led to the development of novel materials for several biological and 
therapeutic applications. Scaffold based 3D models involve culturing cells on or inside a 
naturally or synthetically derived polymers [12]. Natural polymers like collagen or agarose and 
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biocompatible synthetic polymers such as Poly lactic-co-glycolic acid, PEG have been used 
popularly to engineer 3D scaffolds with tuneable properties [12].  
Fabrication techniques like electrospinning can control ECM-mimicking fibrous structure of 
these scaffolds at nanoscale. This helps to establish contacts and guide cells seeded similar to 
in vivo conditions. Electrospinning parameters such as voltage, polymer solution flow rate, 
viscosity of solution, etc. can be optimized to produce scaffold of interest. Besides this, small 
amount of polymers are required in this process making it highly cost effective [13]. 
 
Differences in 3D vs 2D culture 
Studies have suggested that cells cultured in 2D are different from 3D with respect to 
morphology, growth kinetics and genotypic/phenotypic traits [14]. Cells grown on 2D have a 
different morphology as compared to 3D cultures. Gurski et al [15] observed that prostate 
cancer cells seeded on a plastic layer had a spread-out morphology whereas they acquired 
round clustered morphology when cultured in 3D hyaluronic acid hydrogels. Cells in 3D culture 
possess growth kinetics similar to in vivo tumors [16]. Akin to this feature, metabolic activity of 
cells cultured in 3D is markedly different from 2D cells as they have more barriers for diffusion of 
endogenous substrates [17]. Breast cancer cells seeded on 3D chitosan scaffold were found to 
produce more glucose and lactate compared to monolayers [18].  Many studies have 
demonstrated that 3D culture affects genotypic and phenotypic characteristics of cells [19, 20]. 
The genotype of cells cultured as 2D is very different from patient derived tumor samples 
however it matches with cells cultured as 3D [21]. Seminal work in this field highlights that the 
features demonstrated by 3D models such as clustered morphology, growth kinetics, metabolic 
profile and drug resistance resemble those of in vivo tumors [22-24].  
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Applications in anti-cancer drug screening 
Further, cells cultured as 3D respond to anti-cancer drugs in a different manner compared to 2D 
[25]. Therefore, anti-cancer drug/s screening was performed in soft agar assays, a gold 
standard, for several years [26]. Cells grow in soft agar assays in an anchorage independent 
manner and this growth is strongly correlated to tumorigenicity in animal models. But this assay 
is usually slow, labor-intensive and inconsistent because of subjective definitions of colonies 
[27]. 
Using a novel hanging drop technique in 384 well plate, spheroids were formed robustly to 
handle high throughput screening [28]. When anticancer drug sensitivity was tested, cells in the 
3D model showed significantly more viability compared to 2D culture upon treatment with 5-
Fluorouracil (an antimetabolite). In contrast, treatment with Tirapazamine (hypoxia activated 
drug) resulted in higher cytotoxicity in 3D due to presence of hypoxia.  
Human oral cancer cells seeded in engineered 3D poly lactide-co-glycolide (PLG) scaffolds 
resulted in decreased sensitivity to PI3-kinase inhibitor LY294002 in contrast to 2D cells 
suggesting that drug efficacy is dependent upon microenvironmental factors such porous 
structure of 3D PLG scaffolds [21]. The importance of specific microenvironment in this study 
was further enhanced by the lack of drug resistance exhibited in a control 3D Matrigel model. 
On similar lines, Iwase and co-workers developed a 3D model consisting of hepatic cancer 
sheet sandwiched by two collagen sheets in order to mimic natural tissue organization found in 
vivo i.e. cancer cells surrounded by stroma [29]. Upon treatment with doxorubicin it was 
observed that 3D culture was resistant as compared to 2D. Some groups recently have 
developed 3D culture models with a dynamic setup to enable a more accurate prediction of 
chemotherapeutics administered intravenously in vivo. Multicellular tumor spheroids of breast 
cancer (MCF-7) were generated and cultured in a microfluidic device using photolithography 
that simulated conditions in vivo [30]. Treatment by doxorubicin in static as well as dynamic 
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conditions resulted in decreased drug sensitivity of 3D spheroids compared to monolayer 
cultures. 
Human epidermal growth factor receptor 2 (HER2) positive subtype breast cancer cells in 
laminin rich 3D ECM gels acquired a switch in HER2 downstream signalling pathways from 
PI3K-AKT to RAS-MAPK [31]. This switch was not observed in 2D cells. In addition, 3D culture 
of AU565 and SKBR3 cells showed opposing sensitivities to Transtuzumab (HER2 targeted 
antibody), even though they possess same levels of HER2 family proteins.  
Doxorubicin (DOX) micelles delivered to multicellular tumor spheroids of breast cancer cells 
could be visualized through fluorescence microscopy depicting accumulation of DOX micelles 
on the surface of spheroids between cells [30]. This spatial information about DOX micelles can 
help us to understand the drug penetration and carrier effects. Similarly, intracellular trafficking 
of histamine-functionalized copolymer DOX micelles was performed in spheroids of breast 
cancer cells. Compared to 2D, the co-localization of DOX in lysosomes was much lesser in 
spheroids suggesting difficulty to penetrate inside the cellular aggregates [32]. In another study, 
polymersomes loaded with DOX and paclitaxel required longer exposure time for eliciting 
cytotoxic response in 3D spheroid model of head and neck cancer as compared to 2D [33]. 
Taken together, it is clear that 3D culture models offer cues resembling the native tumor 
microenvironment that shape the response of drug/s making it significantly different from 2D. In 
addition, since most 3D models confer drug resistance arising from diffusional barriers 
compared to 2D, they can be used to eliminate or optimize drug candidates that depict good 
sensitivity in 2D cytotoxicity assays. This will help in reducing costs and saving time for drug 
discovery and development process. 
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Tumor microenvironment in cancer progression 
Complex mechanisms and inter-related signalling pathways shape the onset and progression of 
cancer. The microenvironment strongly influences the homeostasis and development of normal 
and malignant tissues [34]. In all tissues, multiple types of cells co-exist surrounded by the ECM 
and endogenous chemicals (chemokines, growth factors, etc.). The interplay amongst these 
components and cells result in their specific function. In a similar fashion, tumor tissues are also 
regulated by their physiological milieu. Neoplastic cells in solid tumors reside along with stromal 
cells (epithelial cells, fibroblasts, dendritic cells, macrophages, vascular endothelial cells) in 
ECM. During tumor development, diffusional gradients in oxygen and nutrients, ECM density, 
activation of immune cells, induction of growth factors influence disease progression. Invasion 
and metastasis, the final stages of any cancer, also occur due to several survival mechanisms 
adopted by aggressive tumors in communication with neighbouring environment [14, 22]. 
 
Breast cancer and its hallmarks during tumor progression 
Breast cancer is a clinically heterogeneous disease that leads to 10–15% of patients developing 
aggressive tumors/ distant metastases within a few years of primary tumor detection [35]. This 
progression of breast cancer is typically categorized by the ‘stage’ of the disease such as non-
invasive (stages 0-2) to invasive (stages 3-4) stage. Interestingly, as per the National Cancer 
Institute’s database, the five-year survival rates drop from 100% in stage 0 to 22% in stage 4. 
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Clinically, the breast tumor progression involves dynamic organization of epithelial cells with 
stromal cells as represented in Figure 1 (upper panel). The primary cancer cells and cellular as 
well as acellular 
components (ECM) of 
tumor 
microenvironment 
evolve with tumor 
progression from 
primary to invasive 
and metastatic stage 
Figure 1 (lower 
panel). This change is 
caused by altered 
physicochemical 
features in the tumor 
microenvironment 
such as hypoxia, 
acidic pH, levels of reactive oxygen species/ metabolic markers, matrix stiffness and porosity 
[36]. Further, the development of advanced breast cancer from ductal carcinoma in situ exhibits 
certain hallmarks that characterize tumor progression. Epithelial to mesenchymal transition 
(EMT), collective cell migration and angiogenesis are the most common hallmarks that are 
described in the following section [1]. 
Epithelial to mesenchymal transition  
Epithelial cancer cells acquire ability to invade, disseminate from primary tumors and 
metastasize to other organs. This change in their programming is known as epithelial to 
Figure 1: Schematic of breast cancer progression [1]. 
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mesenchymal transition (EMT). As seen from Figure 1, the morphology of epithelial cancer cell 
changes to mesenchymal i.e. invasive cancer cell type during this process. At the gene level, 
EMT is characterized by increased expression of transcriptional factors such as Snail, Slug and 
Twist, as well as mesenchymal markers like vimentin and fibronectin [1]. Additionally, some 
studies report loss of E-cadherin that promotes cell-cell adhesion making these cancer cells 
disseminate from the primary tumor site. Moreover, a “cadherin switch” is observed with gain of 
N-cadherin, which enables transition to the mesenchymal phenotype [37]. Cumulatively, this 
classical reprogramming of epithelial cells to mesenchymal type has been investigated in many 
types of solid tumors making it an accepted hallmark of cancer progression. 
Collective cell migration 
During the EMT, cancer cells can detach from the primary core tumor either as a single cell or 
as a collective cohort of cells [38]. This cohort of cells retains cell-cell adherent junction proteins. 
These cells interact dynamically with the neighbouring environment and generate physical 
forces or traction to provide motility to primary tumor. 
Angiogenesis 
Most of the solid tumors are avascular, and can grow up to a size of 1–2 cubic millimetres [39]. 
Beyond this size, the oxygen and nutrient supply to primary tumor reduces greatly. This 
generates a region of hypoxia in these tumors. In such scenario, these tumor cells fulfil their 
need by recruiting surrounding host blood vessels that can subsequently infiltrate the tumor 
mass, allowing for propagation of tumor and potential for metastatic spread of tumor mass via 
blood. This process is called angiogenesis. The induction of angiogenesis is found to be 
associated with upregulation of growth factors such as basic fibroblast growth factor and 
vascular endothelial growth factors (Vegf).  
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Changes pertaining to ER + subtype breast cancer progression 
ER-alpha has been established as a prognostic factor for breast cancer patients with ER+ 
subtype [40]. Mechanistic studies on survival pathways in ER+ breast tumor progression 
indicate that early stage tumors are majorly driven by ER signalling pathway while advanced 
stage tumors lose dependence on this pathway due to genetic or post-translational loss of ER 
[41]. ER+ breast cancers are effectively managed by endocrine therapy during an initial period 
of five years. However, around 30% of patients develop endocrine resistance and metastases in 
the long term [42].  
Clinical literature suggests dependence of advanced stage ER+ tumors on growth factor 
receptors as alternative survival pathway [42]. Therefore, drugs targeting receptor tyrosine 
kinase such as tyrosine kinase inhibitors and antibodies are employed to combat endocrine 
resistance during the later stages of the disease [43]. For illustration, Transtuzumab, a human 
epidermal growth factor receptor (HER2) antibody, was used to treat patients in clinical trials 
that had acquired endocrine resistance. This study indicated that complete pathological 
response in patients improved after administration of HER2 targeted agents [44]. 
Additionally, many therapies incorporate use of chemotherapeutics such as doxorubicin (acting 
on all actively proliferating cells) along with targeted inhibitors to improve efficacy and prolong 
lifespan of advanced stage patients [44].  
 
Importance and unmet need for stage-specific in vitro tumor models   
The dynamic progression of breast cancer is presently investigated using 2D tumor cell line 
cultures and in vivo animal models. In 2D cell culture models, researchers often use non-
invasive cell lines like MCF7/T47D to mimic early stage and invasive cell lines like MDA-MB-231 
to capture the late stage of the disease [45]. These cell lines are derived from patients 
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belonging to early and late metastatic stage, respectively. However, such use of cell lines with 
different molecular signatures cannot reliably depict progression of tumor taking place within a 
patient with over time. Other studies involve manipulations in the same cell line by exposure to 
artificial conditions like hypoxic chambers or silencing/overexpression of genes to mimic tumor 
progression [46]. These studies also have limitations because artificial manipulation of cellular 
machinery can dysregulate other mechanisms influencing tumor progression [47].  
Mouse xenograft models may be better in vivo tools, as they possess a more complex 
physiological system. However, the target tissue expression, metabolic processes and immune 
system are significantly different from humans resulting in varied toxicity/efficacy profiles of 
potential drug candidates [48, 49]. Alternatively, breast tumor biopsies and tissue microarrays 
can be useful in identifying metastatic and aggressive tumor phenotypes but lack of availability 
of biologically matched tumor samples limits progress in the field [50].  
Thus, there is an unmet need to develop in vitro models that can mimic the natural tumor 
progression in real time without use of artificial conditions. Such in vitro models would be of 
great value to screen drugs that act on various molecular targets activated at different stages 
during tumor progression. Besides establishing the safety and efficacy of potential drug 
candidates, such models could also provide the right platform to study major molecular 
pathways that regulate tumor growth pertaining to specific stages in tumor progression. This 
could allow researchers to develop therapies that can combat the disease in a more effective 
manner. 
Therefore, we rationally designed stage-specific models to mimic breast cancer progression by 
controlling the size of microtumors. Tumor size is a widely used prognostic marker of stage-wise 
breast cancer progression [51]. Hence, we developed uniform, size-controlled microtumors 
where size was controlled by seeding cells on hydrogel microdevices with uniform size 
microwells fabricated using with micropatterning technique [52]. As demonstrated in our 
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previous work [53], these novel size-controlled microtumor models recapitulated physiological 
milieu of solid tumors such as development of hypoxia, induction of metabolic stress and central 
necrotic zone of cells surrounded by peripheral proliferating cells.  
In the current work, we hypothesized that microtumor size-dependent physicochemical changes 
in the tumor microenvironment will lead to progression of non-invasive breast cancer 
microtumors (T47D) to aggressive advanced stage microtumors defined by acquisition of 
mesenchymal phenotype and migratory behaviour. We predicted that 600 µm microtumors 
(referred to as large microtumors hereafter) would resemble advanced stage breast cancer 
characteristics such as biochemical features and response to drug/s due to similarity with 
pathological microenvironment of advanced stage clinical samples, achieved by virtue of 
increased microtumor size. Similarly, 150 µm microtumor (referred to as small microtumors 
henceforth) will mimic attributes of early stage breast cancer. 
Our data suggests that large microtumors depict the late stage of the disease while small ones 
show the traits of early stage tumors. Additionally, clinically observed hallmarks of late stage 
tumors such as loss of ER-α and endocrine resistance were observed in large microtumors but 
not in the small ones. In addition, mechanisms for observed drug resistance were explored. 
Cumulatively, these results indicate that the stage specificity and high clinical relevance of size-
controlled microtumor models can be effectively exploited for discovery of breast cancer 
therapeutics.   
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2. MATERIALS AND METHODS 
 
2.1 Cell culture 
 
The T47D breast cancer cell line was received from Prof. Steffi Oesterreich’s lab (Magee 
Women’s Research Institute, UPCI, Pittsburgh). All the cell culture supplies and media were 
obtained from Corning and Mediatech, respectively unless specified. T47D cells were cultured 
in T75 flasks that contained DMEM medium supplemented with 10% FBS (Hyclone, Utah, USA) 
and 1% penicillin-streptomycin. T47D cell flasks were cultured in a humidified incubator 
maintained at 37 °C and 5% CO2. Prior to seeding into hydrogel microwell arrays, cells were 
cultured to achieve 40-60% confluence. 
 
2.2 Materials and reagents 
 
All chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless specified. The 
antibodies (anti ER-alpha F-10 sc8002, anti-EGFR 1005 sc03G) were procured from Santa 
Cruz Biotechnology (California, USA). The antibody anti-beta actin (MA5-15739-D680) was 
purchased from Thermo Scientific Inc. (Rockford, USA) while anti-phospho EGFR (Tyr 845) 
[2231S], anti-Akt [9272S], anti-phospho Akt (Ser 473) [4060S], anti-ERK 1/2 [9102S], anti-
phospho ERK 1/2 (Thr 204/Tyr 202) [4370P] were obtained from Cell Signaling Technology 
(Danvers, MA, USA). All secondary antibodies (Dylight 690, 800, Alexa Fluor 488, 594) were 
secured from Thermo Scientific Inc. (Rockford, USA). 4-hydroxytamoxifen was purchased from 
Sigma Aldrich (St. Louis, MO). Ruthenium-tris (4, 7-diphenyl-1, 10-phenanthroline) dichloride 
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(Ru-dpp) was acquired from Santa Cruz Biotechnology, (California, USA). 2’, 7’ –
dichlorodihydrofluorescin diacetate (DCHFDA) was procured from Cayman Chemicals 
(Michigan, USA). Propidium iodide was obtained from Sigma Aldrich (St. Louis, MO) and 
RNAse I solution from Thermo Scientific Inc. (Rockford, USA).   
 
2.3 Three dimensional (3D) microtumor fabrication 
 
Microtumors of breast cancer cells (T47D) were fabricated as detailed in the previous work [53]. 
Briefly, using cylindrical polydimethylsiloxane (PDMS) posts of 150 and 600 µm (diameter and 
height), wells were imprinted on polyethylene glycol dimethacrylate (PEGDMA) substrate 
containing 1% photoinitiator (Irgacure, BASF, USA) and 20% PEGDMA in a photocrosslinking 
technique.  After crosslinking of hydrogel and formation of wells, the devices were sterilized in 
70% isopropanol under UV for 45 min. Following this process, devices were washed three times 
with DPBS to remove isopropanol and observed under microscope for any imperfections/air 
bubbles. T47D cells (2x 104 cells/µL) were added to each device with 1 cm x 1cm dimensions in 
a 24 well plate and allowed to settle for 30 min. This was followed by another round of cell 
addition. After this step, excess cells were washed away carefully by DPBS, and media was 
added to the wells containing devices in culture plates and kept in the incubator.  
 
2.4 Reactive oxygen species and intra-tumoral oxygen measurement 
 
These experiments were performed to analyse whether microtumor size affects 
physicochemical features of solid tumors such as reactive oxygen species and hypoxia. T47D 
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microtumors were cultured as described above for 6 days by replenishing wells with fresh media 
each day after removal of 50% media. For reactive oxygen species detection, 10 µM DCHFDA 
was added to the microtumors and cultured for 3 hours in an incubator. After a wash with PBS, 
microtumors were imaged using a confocal microscope (Olympus Fluoview, Olympus). To 
determine intra-tumoral oxygen availability, fluorescence of Ru-dpp, (excitation, λmax 455 nm, 
emission λmax 613 nm), was used. Ru-dpp fluorescence is quenched in presence of oxygen 
thus enabling us to determine regions of hypoxia. Microtumors were incubated in 10-4 µM Ru-
dpp solution for 3 hours and images of Ru-dpp stained microtumors were acquired on a 
confocal microscope (Olympus Fluoview, Olympus). Background fluorescence was accounted 
by imaging culture media containing Ru-dpp without microtumors.  
 
2.5 Metabolic activity measurement in microtumors 
 
In order to study effect of microtumor size on growth of microtumors, metabolic activity of small 
and large microtumors was assessed using the standard alamarBlue® assay [54]. This assay is 
based on the principle that the viable cells reduce resazurin to resorufin. Resazurin, the main 
component of alamarBlue® reagent, is a non-toxic, cell permeable compound that is blue in 
color and virtually non-fluorescent. Upon entering cells, resazurin is reduced to resorufin, a 
compound that is red in color and highly fluorescent. Viable cells continuously convert resazurin 
to resorufin, increasing the overall fluorescence. The conversion measured in terms of 
fluorescence of the dye is proportional to viability/metabolic activity of the samples. This assay 
has been optimized and used in previous studies from the lab [55]. 
The T47D microtumors were cultured as mentioned before in a 24 well plate. On the required 
day (1, 3 or 6), 10% alamarBlue® solution (Thermo Scientific, Rockford, USA) was freshly 
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prepared in growth media (DMEM+10%FBS+1%Penicillin/Streptomycin). The media from all 
wells was discarded and 600 μL of 10% alamarBlue® solution was added to each well 
containing microtumors. After three hours of incubation (37°C), the plate was removed and the 
solution was gently mixed using a micropipette. The supernatant from wells was transferred to a 
96 well plate and the culture plate was replenished with fresh media. The 96 well plate was read 
for fluorescence at excitation 530 nm and emission 590 nm by a microplate reader (H1 Synergy, 
Biotek Instruments, Winooski, VT, USA). After required days of culture, the 24 well plate was 
removed from incubator and alamarBlue® assay was performed similarly.  The percentage (%) 
growth for each device containing microtumors was calculated as per the formula [(Average of 
fluorescence values at Day # (1, 3 or 6)/ Average of fluorescence values at Day 1)] x100. 
 
2.6 Cell cycle analysis in microtumors 
 
We further investigated effect of various physicochemical changes in the tumor 
microenvironment (hypoxia, ROS) on cell cycle progression in small (150 µm) vs. large (600 
µm) microtumors. Small and large microtumors were cultured as outlined above. The media was 
changed every day. After required days in culture (1, 3 or 6), microtumors were harvested gently 
and collected in microcentrifuge tubes and pelleted using centrifugation for 3 min at 1200 RPM. 
The pellet was washed with PBS and trypsinized for 7-10 min. After quenching the cell 
suspension with media, cells were pelleted using centrifugation. The pellet was suspended in 
500 µL of cold PBS. The cell suspension was added dropwise to 500 µL of cold absolute 
ethanol. The sample was observed for clumping and any visible clumps were removed using 
tweezers. The microcentrifuge tubes sealed with parafilm were stored at 4 °C overnight. After 
this fixing process, cells were washed with cold PBS and centrifuged at 400 RPM for 10 min. 
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The pellet was resuspended in 300 µL of 50 µg/mL propidium iodide solution (containing 100 
µg/mL RNAse I solution). The tubes were vortexed briefly and incubated at 37 °C for 30 min. 
The data was acquired on a flow cytometer (BD Accuri C6, BD Biosciences, New Jersey, USA). 
For all the groups, total number of events recorded in the FL2-A vs FL2-H channel was 15000. 
The histograms were analysed using ModFit LT software (Verity Software House, Maine, USA).  
 
2.7 RNA isolation and q-PCR analysis 
 
In order to study the changes in the expression of genes involved in various pathways (e.g. 
epithelial-mesenchymal transformation, EMT) in microtumors, mRNA expression was analysed 
by quantitative PCR. RNA isolation was performed using GeneJET RNA purification kit (Thermo 
Scientific, Lithuania, EU) as per the manufacturer’s instructions. Frozen microtumor samples 
were lysed in the commercially supplied lysis buffer with addition of β-mercaptoethanol by 
vortexing for 5 min, ethanol addition and incubation at room temperature for 5 min. The mixture 
was passed through GeneJet purification columns and washed multiple times with kit buffers at 
12000 RPM for 1 min. Total RNA adsorbed onto the columns was eluted by using nuclease free 
water provided with the kit. RNA concentration was measured using Nanodrop and RNA quality 
was determined by absorbance ratio at 260/280 nm. Estrogen receptor alpha mRNA expression 
was estimated by qRT-PCR after generating cDNA using 500 ng mRNA and iTaq Universal 
SYBR Green RT-PCR kit (BioRad Laboratories Inc., USA). Briefly, reaction mixture containing 2 
µL cDNA, 5 µL of 2X SYBR green master mix and respective primers (0.2 µM) was amplified in 
triplicates. For estrogen receptor, the forward primer sequence is 5’ 
AACCGAGATGATGTAGCCAG 3’ while reverse primer sequence is 
5’ CAGGAACCAGGGAAAATGTG 3’. 
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Other primer sequences were as described in previous work [53]. The amplification protocol 
used was 40 cycles of denaturation for 15 sec at 95 °C, annealing for 30 sec at 55 °C and 
extension for 30 sec at 72 °C (7500 Fast Real-Time PCR System, Applied Biosystems, 
California, USA). mRNA expression was calculated using 2-ΔΔCt method [56] and depicted as the 
mean ± SEM as fold change compared to the controls (day 1 samples).  
 
2.8 Protein extraction and western blotting 
 
The goal of this experiment was to evaluate changes in the expression of proteins of interest as 
a function of time in culture and microtumor size. Frozen microtumors were homogenized in 
RIPA buffer containing Tris (50 mM, pH 7.4), NaCl (150 mM), sodium deoxycholate (0.5%), 
nonyl phenoxypolyethoxylethanol-40 (1%), phenylmethylsulfonyl fluoride (0.05 mM), protease 
inhibitor cocktail for mammalian tissue extract and phosphatase inhibitor cocktail (Sigma-Aldrich 
Inc., Milwaukee, USA). Total protein content was quantified by Coomassie Plus (Bradford) 
Assay kit (Thermo Scientific, Rockford, USA).  
Fifty microgram protein samples were separated by 8-10% SDS-PAGE and transferred onto 
0.45 µm PVDF membrane (Thermo Scientific, Rockford, USA). The PVDF membrane was 
blocked in Odyssey Blocking Buffer (PBS based), (LiCor Biosciences, Nebraska, USA) for 2 h at 
room temperature. Further, blots were probed with primary antibodies (1:1000), by incubating 
overnight at 4 °C. Later on, the membrane was washed thrice with PBS containing 0.1% Tween-
20 (PBST) and incubated with respective fluorescently conjugated secondary antibodies for 2 h 
at room temperature on a rocking platform. The membranes were developed by scanning in 
Odyssey Infrared Imaging System (LI-COR® Biosciences, Lincoln, USA) and coloured images 
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were converted to grayscale by using Odyssey 3.0 software. Densitometry analysis of blots was 
done by ImageJ Software (National Institute of Health, USA).  
 
2.9 Immunofluorescence studies 
 
The immunofluorescence studies were used to probe differences in intra-tumoral and 
subcellular localization of proteins as a function of microtumor size. Harvested microtumors 
were fixed with 4% paraformaldehyde for 30 min at room temperature, washed with PBST to 
remove residual PFA and again fixed with 95% methanol on ice for 15 min. Permeabilization 
with 0.1% Triton X-100 was done for 1.5 hours followed by blocking with 3% BSA to avoid non-
specific binding. Microtumors were placed on depression slides and incubated with primary 
antibody (1:100) overnight at 4 °C in a humidified chamber along with a negative control 
(without primary antibody). After washing three times with PBST, microtumors were incubated 
with fluorescently labelled secondary antibodies for 1 h at room temperature. Nuclei were 
stained by incubating with Hoechst (1:300) at 4 °C overnight. After two washes with PBS, 
glycerol was added to stained microtumors and kept at 4 °C until confocal imaging.  Images 
were acquired on confocal microscope (Olympus Fluoview, Olympus) as a z-stack containing a 
series of 5-µm slices using 10X (lower magnification) or 40X (higher magnification) objectives 
with or without zoom factor. The images are presented as 2D projection of maximum intensity. 
 
2.10. Measurement of 4-Hydroxytamoxifen (4-OHT) response in microtumors 
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As mentioned in the introduction, several studies have reported differential drug response in 2D 
vs. 3D cultures [5, 14, 25, 30]. With our ability to control precisely the microtumor size, we 
sought to determine if the drug response would be affected by microtumor size and possible 
mechanisms for such differential response. As the cell line used throughout this study was 
T47D, ER+ cell line, selective estrogen receptor modulator (SERM), 4-OHT was selected as a 
drug, which also remains the mainstay in the clinical management of ER+ patients. The T47D 
cells were seeded in hydrogel devices (1 cm x 1 cm) kept in 24 well plates and cultured for three 
days as described previously. For drug treatment, 10 mM 4-OHT (stock solution) was 
solubilized in DMSO. Further, 50 μM 4-OHT in growth media was prepared and stored away 
from light. On day 3, media from wells was removed and metabolic activity was assessed by 
adding 600 μL of 10% alamarBlue® solution (Thermo Scientific, Rockford, USA) freshly 
prepared in growth media. Only 10% alamarBlue® solution was used as a blank sample and the 
plate was kept in incubator (37°C). After three hours of incubation, the plate was removed and 
the solution was gently mixed using a micropipette. Seven devices per condition (untreated, and 
treated for both 150 µm and 600 µm) were used. Supernatant (150 μL x3) from each well was 
assayed for fluorescence intensity using excitation 530 nm and emission 590 nm by a 
microplate reader (H1 Synergy, Biotek Instruments, Winooski, VT, USA). After removal of the 
remaining alamarBlue® solution, 600 μL of drug solution was added to the wells (treatment 
groups) while fresh media with equal volume of DMSO was added to wells (control/vehicle 
groups). The culture plate was replaced back into the incubator for a period of three days. On 
day 6, the microtumors were analysed for metabolic activity again using alamarBlue® assay.  % 
Growth for microtumors in each device was calculated with vehicle treated control taken as 
100% growth as per the formula: 
% Growth = [(Average of fluorescence values at Day 6)/ Average of fluorescence values at Day 
3)] x100.   
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2.11 4-OHT quantification in microtumors by mass spectrometry 
 
We further quantified the amount of 4-OHT in the treated microtumors. The harvested 
microtumors were washed with DPBS, pelleted and potassium chloride -Tris HCl buffer was 
added. This mixture was sonicated for 15 seconds and incubated on ice for 2 hours. The 
mixture was analysed by LC-MS/MS method. 
2.11.1 Analytical 
An LC-MS/MS method was used to quantitate 4-OHT (Sigma-Aldrich, St. Louis, MO) in 
microtumor lysate using [D6]-4-hydroxytamoxifen (Toronto Research Chemicals, North York, 
Ontario, Canada) as an internal standard. 
The HPLC method consisted of an Agilent 1100 autosampler and Agilent 1100 binary pump 
(Agilent Technologies, Palo Alto, CA) using a Synergi Polar-RP 80A (4 µm particle size, 2 mm x 
100 mm) column at ambient temperature. Mobile phase solvent A was 0.1% formic acid (v/v) in 
methanol, and mobile phase solvent B was 0.1% formic acid (v/v) in water. Isocratic mobile 
phase conditions were used with 78% mobile phase A pumped at 0.3 mL/min for the entire 
duration of the 5 min run time. Retention time was 1.5 min. 
A Waters Quattro Micro (Milford, MA) mass spectrometer was used in positive-ion MRM mode 
(4.0 kV capillary voltage, 40 V cone voltage, 22 V collision voltage) to monitor m/z 388.0>72 for 
4-hydroxytamoxifen and m/z 394.0>78.0 for [D6]-4-hydroxytamoxifen.  
2.11.2 Sample preparation 
Standards (10, 30, 100, 300, 1000, 3000, 5000 and 10000 ng/mL) were prepared in a 50/50 
mixture of potassium chloride lysis buffer and human plasma (Lampire Biological Laboratories 
Inc., Pipersville, PA). For microtumor samples, 50 µL of microtumor lysate sample was 
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combined with 50 µL of blank plasma to match the 100 µL calibrator sample matrix and volume. 
Resulting microtumor lysate sample concentrations were corrected for the dilution after analysis. 
Internal standard solution (10 µL of 1 µg/mL) was added to each tube prior to addition of 
sample. A volume of 300 µL of ice cold methanol was then added and the samples vortexed for 
1 min using a Vortex Genie-2 (Scientific Products, Bohemia, NY). Samples were then 
centrifuged at 12,500 x g for 3 min and 100 µL of the resulting supernatant was transferred to 
an autosampler vial. The sample injection volume was 5 µL. 
 
 2.12 Statistical analysis  
 
Results are depicted as mean ± SEM (standard error of mean) from three independent 
experiments each with triplicates or more. A one-way or two-way analysis of variance (ANOVA) 
followed by a Tukey’s multiple comparison-test was used to compare control and test groups. A 
p-value less than 0.05 was considered significant. Graph Pad Prism (V6.0) was used to perform 
the statistical analysis. 
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3. RESULTS AND DISCUSSION 
 
3.1 Microtumor size affects physicochemical factors in the tumor 
microenvironment. 
 
We have previously demonstrated the use of microfabrication to generate hundreds of uniform 
breast microtumors with precisely controlled size [53]. As depicted in Fig. 2A (left panel), T47D 
breast cancer cells, representative of ER+ subtype, were seeded in 150 μm and 600 μm non-
adhesive PEGDMA hydrogel microwells. After six days of culture with daily media change, 
uniform microtumors were obtained as shown in Fig. 2A (right panel).  
To establish whether these engineered microtumor models show size-dependent changes in the 
physicochemical features of the microenvironment as observed in solid tumors in vivo, we 
analysed characteristic features of advanced stage solid tumors such as hypoxia, reactive 
oxygen species and rate of cellular proliferation. We predicted that large microtumors would 
show increased levels of hypoxia, ROS and exhibit higher proliferation akin to features of 
advanced stage breast tumors [36]. 
Firstly, hypoxia was measured by assessing intratumoral oxygen availability in the microtumor 
models through addition of Ru-dpp followed by confocal imaging. The fluorescence of Ru-dpp, 
quenched under normoxic conditions, is enhanced in regions of hypoxia. This principle allows 
us to visualize spatial distribution of hypoxia in microtumors. Ru-dpp staining (indicated by red) 
was enhanced to a greater extent in large microtumors in contrast to the smaller ones (Fig. 2B 
left panel). 
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Figure 2: Microtumor size affects physicochemical features of tumor microenvironment 
A) T47D cells were cultured in PEGDMA hydrogel array and seeded in devices with, 150 µm 
and 600 µm size microwells, left panel. Microtumors harvested at day 6 (right panel) represent 
uniform size microtumors. B) Ru-dpp staining (red color) of microtumors harvested on day 6 
revealed heterogeneous presence of hypoxic cells in large (600 µm) microtumors (bottom left) 
as compared to small (150 µm) small ones (top left). DCHFDA staining of microtumors 
harvested on day 6 showed negligible ROS signal (green color) in small microtumors (top 
right) in contrast to the large ones (bottom right). C) Hif-1α and Vegf were found to be 
upregulated in large microtumors at day 6 by western blotting. D) Large microtumors showed 
higher percentage growth at day 6 and 3 when normalized to day 1 (measured by metabolic  
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Further, ROS were visualized in the microtumors using the 2’, 7’ –dichlorofluorescin diacetate  
(DCHFDA) probe. DCHFDA a non-fluorescent compound, that becomes fluorescent after 
reaction with hydroxyl and peroxyl ROS. After incubation with DCHFDA for 3 hours, confocal 
microscopy revealed that large microtumors possessed a central core where ROS (green 
staining) was detected (Fig. 2B right panel). No ROS production was observed in small 
microtumors (150 μm). 
For further confirming the presence of hypoxia in large microtumors, we measured protein 
expression of two molecular markers of hypoxia, namely hypoxia inducible factor 1 alpha (Hif-
1α) and vascular endothelial growth factor (Vegf). Hif-1α and Vegf have been found clinically to 
promote tumor progression [57]. Western blotting confirmed the increased expression of Hif-1α 
in large microtumors (600 μm) as compared to the small ones as well as in 2D cells (Fig. 2C). 
Vegf, a downstream effector of Hif-1α also had higher expression in large microtumors than 
small ones (150 μm) (Fig. 2C).  
To assess the rate of proliferation in a microtumor model, a standard assay, alamarBlue® assay 
[54], that measures cellular metabolic activity was used. The enzymatic reduction of resazurin to 
resorufin by nicotinamide adenine dinucleotide (NADH) dehydrogenase in this assay provides 
estimate of metabolic activity. Highly metabolically active cells exhibit greater rate of 
proliferation [54]. The percentage growth (rate of proliferation) of large (600 μm) and small (150 
μm) microtumors was calculated by normalizing with their respective metabolic activity on day 1. 
A two-way ANOVA was performed to test the effects of microtumor size and time (independent 
variables) on percentage growth of microtumors (dependent variable). There was significant 
effect of microtumor size on percentage growth of microtumors (F [1, 18] =22.22 and p=0.0002) 
activity assay) compared to small ones (* p<0.05, n=4 devices/group, two-way ANOVA with 
Tukey’s post hoc analysis). 
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as well as time (F [2, 18] =27.81 and p<0.0001). In addition, an interaction between microtumor 
size and time was found to be significant (F (2, 18) =5.591 and p=0.0129). Tukey’s post-hoc 
analysis revealed that large microtumors (600 μm) had significantly higher metabolic activity 
(Fig. 2D) on days 3 and 6, compared to day 1. Importantly, the metabolic activity of large 
microtumors on days 3 and 6 was significantly higher than that of smaller microtumors.  
Taken together, these results indicate that controlling microtumor size can affect the 
physicochemical features of the tumor microenvironment. Hypoxia, a common feature of 
advanced solid tumors in vivo [58], was found to be upregulated at the molecular level through 
induction of Hif-1α in large microtumors. Additionally, downstream effector, Vegf, directly linked 
to this pathway was also elevated in the large microtumors suggesting that large microtumors 
acquire some of the characteristics of pro-angiogenic tumors, one of the hallmarks of tumor 
progression [39].  
Hypoxic cells have been shown to generate ROS [59] that justifies presence of ROS in large 
microtumors. However, the interplay between ROS and Hif-1α is complex as studies show that 
effect of ROS on Hif-1α depends on various factors like degree of hypoxia and forms or 
intracellular localization of ROS [60]. Metabolic activity assessed by enzymatic reduction assay 
is a surrogate of cell number and indicator of cellular proliferation [54].  
Interestingly, higher rate of proliferation observed in large microtumors as compared to the 
smaller ones (150 μm) suggest that large microtumors may be considered more aggressive 
than the small ones. Indeed, clinically advanced stage tumors are reported to possess higher 
proliferation index [61]. For example, in a large cohort of breast cancer patients, Ki-67, a 
proliferative marker, was found to be an independent prognostic factor [61]. Patients with Ki-67 
less than 15% had significantly greater overall survival than those with Ki-67 with greater than 
45%. This indicated that advanced stage patients with lesser survival rates had tumors with 
higher proliferative index values. 
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3.2 Three-dimensional cultures of T47D microtumors affect cell cycle 
progression. 
 
We investigated whether the observed microtumor size-dependent changes in physicochemical 
factors (hypoxia, ROS) affect their cell cycle progression. We also sought to determine if the 
size-dependent changes in proliferation as estimated by metabolic activity correlate to their cell 
cycle progression in these microtumor models. Cell cycle progression from G0/G1 (gap/DNA 
repair phase), S (synthesis phase) to G2/M (growth/mitotic phase) has been shown to be 
influenced by the tumor microenvironment [62]. Further, oxidative stress induced in cells can 
cause DNA damage and arrest of cells in the G0/G1 phase [62]. On the other hand, a higher 
proliferation index is associated with higher proportion of cells in the G2/M phase [63]. 
Therefore, it was predicted that large microtumors with a higher rate of metabolic activity would 
exhibit higher proportion of cells in G2/M phase. 
Propidium iodide (PI) staining was performed to determine DNA content in cells and scatter 
plots were drawn from flow cytometer. In Fig. 3A, R1 represents forward vs. side scatter that is 
used to eliminate cell debris. R2 depicts side scatter area vs. height, which eliminates doublet 
populations by considering only cells that fall on the line with slope 1 (angle = 45°). R3 presents 
PI channel intensity area vs. height that helps to distinguish different phases of cell cycle 
because DNA content increases proportionally to cell cycle phases (2N in G0/G1 phase, 4N in 
G2/M phase) [62]. Fifteen thousand cells were counted in R3 for all samples. This region is 
converted to histograms and calculated for % cells in each phase by ModFit software.       
The R3 plots showed an increased proportion of cells with much less PI content in large (600 
µm) microtumors (red box, Fig. 3A iii) compared to 2D cells or small (150 µm) microtumors.  
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A one-way ANOVA was performed to analyze effect of culture conditions (2D, 150 µm and 600 
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Figure 3: Three dimensional cell culture of T47D affects cell cycle progression 
A) Scatter plots of T47D cells cultured for 6 days as 2D (i), small microtumors (ii) and large 
microtumors (iii). The corresponding histograms are depicted in red. Note that cell number 
intensity in scatter plots decreases as red>yellow>green>blue. Red box indicates large 
population with low PI content in R3 for large microtumors (iii). B) Quantification of proportion 
of cells in each phase showed increased G0/G1 phase in 3D as compared to 2D. Also, 
decrease in S phase of small microtumors and reduced G2/M phase in large microtumors was 
observed (*p<0.05, n=3, one-way ANOVA, Tukey’s post hoc test). 
 µm microtumor; independent variable) on cell cycle phases (dependent variable). Culture 
conditions significantly affected proportion of cells in G0/G1 phase (F [2, 6] =13.53 and 
p=0.006), S phase (F [2, 6] =7.873 and p=0.021) and G2/M phase (F [2, 6] =33.25 and 
p=0.0006). Results from one-way ANOVA indicated that 3D microtumors consisted of 
significantly higher (75%) proportion of cells in G0/G1 (gap/DNA repair) phase than those in 2D 
cells (65%) suggesting more cells in stationary/repair phase when cultured under 3D 
microtumors (Fig. 3B). Tukey’s post-hoc test suggested that large microtumors had significantly 
less number of cells in the G2/M (growth/mitotic) phase compared to smaller ones. The S-phase 
was reduced to higher extent in small microtumors as compared to 2D. 
The higher proportion of cells in G0/G1 phase in 3D cultures compared to 2D can be explained 
based on the increased barriers for nutrition and oxygen diffusion in 3D model as compared to 
2D, causing more DNA damage [62]. It should be noted that contradictory to our predictions, 
large microtumors also showed decreased percentage of cells in G2/M phase compared to the 
small ones. The DNA damage may likely be a result of hypoxia and oxidative stress that is 
experienced by the cells in the core of large microtumors (depicted in Fig. 2). As mentioned 
previously, oxidative stress-induced damage can make cells quiescent and is a feature of 
clinically advanced solid tumors [64]. However, extrapolation of this feature to large microtumors 
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needs to be considered with other factors that affect cell cycle progression, namely, cell number 
doubling time and synchronization of cell cycles prior to seeding [65].  
 
 
To further evaluate whether observed changes in the cell cycle progression at day 6 could be 
attributed to time-dependent changes during culture, cell cycle analyses of microtumors 
harvested at days 1, 3 and 6 were performed. It was predicted that large microtumors would 
lose G2/M as compared to their day 1 status due to increased oxidative stress with time.  
A one-way ANOVA was performed independently for large and small microtumors to analyze 
effects of time (independent variable) on cell cycle phases (dependent variable). There was 
significant effect of time and cell cycle phases in small microtumors (F [2, 6]=125 and p<0.0001) 
as well as large microtumors (F [2, 6]=315.8 and p<0.0001). Tukey’s post-hoc analysis revealed 
that large microtumors (600 µm) had significant decrease in G2/M phase on day 6 compared to 
day 1 providing support that microenvironmental changes such as hypoxia or oxidative stress 
Figure 4: Time dependent changes in the cell cycle progression of microtumors 
A) Small microtumors had significantly increased S phase on day 3 compared to other 
groups. B) Large microtumors had significantly decreased G2/M phase at day 6 compared to 
other days (*p<0.05, n=3, one-way ANOVA, Tukey’s post hoc test). 
* * 
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may be responsible for reduction in proportion of cells in growth/mitotic phase (Fig. 4B). 
However, this finding needs to be confirmed by inhibiting oxidative stress in large microtumors 
and reassessing cell cycle status. In small microtumors (150 μm), there was a significant 
increase in S-phase at day 3 that reduced at day 6 indicating that they were affected by time-
dependent changes during culture.  
 
3.3 Large microtumors acquire aggressive phenotype. 
 
Figure 5: Large microtumors showcase aggressive traits through migratory behaviour 
and mesenchymal phenotype 
A) Large (600 µm) microtumors show migratory behaviour on day 6 unlike small (150 µm) 
ones. B) Large microtumors had significantly increased VIM, SNAIL, TWIST, SLUG mRNA 
expression without change in E-Cad as compared to small microtumors (*p<0.05, n=3 
devices, one-way ANOVA, Tukey’s post hoc test). 
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To test the hypothesis that 600 µm microtumors acquire aggressive phenotype, we evaluated 
the microscopic changes in large microtumors during 6 days of culture. Interestingly, starting 
from day 4 up to 6 days of culture, about 85 % of large microtumors migrated out of the 
PEGDMA hydrogel arrays while the small ones (150 µm) remained intact inside the hydrogel 
devices (Fig. 5A). 
In order to further determine if this observed migration is due to the molecular changes in the 
signalling pathways reported for classical EMT, gene expression of reported EMT markers 
including Vimentin, Snail, Slug, Twist and E-Cadherin was measured. Large (600 µm) 
microtumors were predicted to have an increased level of mesenchymal markers with loss of 
epithelial marker compared to the smaller (150 µm) ones. 
A one-way ANOVA was performed to analyze effect of culture conditions such as 2D, 150 µm 
and 600 µm microtumors (independent variable) on EMT gene expression (dependent variable). 
All the tested mesenchymal markers including Vimentin (Vim), Snail, Twist and Slug were 
significantly affected (p < 0.05). However, epithelial marker, E-Cadherin (E-Cad) was not 
significantly affected (F [2, 6] =1.411 and p=0.3145). The Tukey’s post-hoc analysis revealed 
that large microtumors had significant upregulation of mesenchymal markers Vim, Snail, Twist 
and Slug without loss of epithelial marker, E-Cad as compared to small microtumors. 
This observed ‘migratory’ behaviour or collective cell migration in large microtumors (600 µm) 
could be linked to the aggressive phenotype of tumors found in advanced stage cancers in the 
clinic [66]. The upregulation of mesenchymal markers at mRNA level confirmed the 
mesenchymal transformation of these non-invasive T47D cells when cultured as 600 µm 
microtumors. Additionally, previous study in these microtumors also demonstrated protein level 
upregulation of mesenchymal markers, Snail and Vimentin [53]. Interestingly, at both mRNA and 
protein level, E-Cad levels did not change significantly with microtumor size (p >0.05). This 
depicted that large microtumors did not follow the classical EMT (upregulation of mesenchymal 
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markers with simultaneous loss of E-Cad). Other studies have also reported that the loss of E-
Cad is not a necessity for EMT [67, 68]. This may represent partial EMT phenotype where cells 
acquire mesenchymal phenotype without loss of epithelial markers like E-Cad. Thus, there 
could be other mechanisms in large microtumors that are responsible for mesenchymal 
characteristics while maintaining their epithelial phenotype [69].  
This observation is also consistent with the ‘collective’ or ‘cohesive’ migration reported in recent 
studies [38]. This ‘migratory’ behavior or collective cell migration in large microtumors could be 
linked to the aggressive phenotype of tumors found in the advanced stage cancers in the clinic 
[66, 70, 71]. Cumulatively, this suggests that large microtumors of T47D behave similar to the 
aggressive advanced breast tumors as demonstrated by mesenchymal marker upregulation and 
migratory phenotype. 
 
3.4 Large T47D microtumors lose ER-α expression at protein level recapitulating 
observations in clinically advanced tumor samples. 
 
The estrogen receptor alpha (ER-α) is responsible for driving the growth of breast tumors with 
an ER+ subtype. It has been widely used as a prognostic marker for ER+ breast cancer 
progression as well as to predict the response to endocrine therapy [72]. Clinically, it is reported 
that ER-α levels are downregulated or lost at both gene and protein levels with tumor 
progression [73]. Therefore, we measured transcriptional and translational expression of ER-α 
in the small and large microtumors.   
We observed no significant changes in the ER-α mRNA levels as a function of microtumor size 
(small 150 µm vs. large 600 µm microtumors) and time in culture (days 1, 3 and 6) (Fig. 6A). 
However, there was a significant loss of ER-α protein expression in the large microtumors at  
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Figure 6: ER-α although unaffected at gene level, is lost at protein level beyond 
day 3 in large microtumors.  
A) ER-α mRNA expression is maintained through all days of culture and not affected by 
microtumor size. B) ER-α protein expression was lost in the large microtumors beyond 
day 3. C) ER-α immunofluorescence (green) images (2D projection of maximum 
intensity) indicated nuclear presence of receptor in the microtumors (high magnification 
images). Large microtumors revealed loss near the core (second row). 
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days 3 and 6 (compared to respective day 1, Fig. 6B). On the contrary, small microtumors did 
not show much change in ER-α protein expression from day 1 to day 6.  
Previous studies have reported ER-α downregulation with hypoxia in breast cancer cell lines as 
well as in clinical samples [74, 75]. In these studies, it was demonstrated that Hif-1α induced by  
hypoxic chambers depleted ER-α protein expression in ER+ cell lines such as MCF-7. Stoner 
and colleagues investigated the mechanisms for the ER-α receptor downregulation and found 
proteasome-mediated degradation triggered due to hypoxia as the underlying cause [74]. Thus, 
loss of ER-α protein in large microtumors may be attributed to the higher levels of hypoxia and 
Hif-1α present only in the large microtumors (Fig. 2B and 2C). 
To further establish link between the loss of ER-α in large microtumors and hypoxia, we 
performed immunofluorescence studies on microtumors cultured for 1, 3 and 6 days. This 
technique enabled to obtain spatial distribution of ER-α in the microtumors. As shown in Fig. 
6C, the ER-α expression in small microtumors was maintained through all days of culture except 
for some loss near the core at day 6, thus confirming our data of protein expression in Fig. 6B. 
On the other hand, large microtumors (600 µm) showed decreased ER-α expression in the core 
(Fig. 6C, low magnification panel) at day 3 and day 6 confirming results of western blotting 
(Fig. 6B).   
As hypoxia was found to be present near the core of large microtumors (Fig. 2B), the reduced 
fluorescence of ER-α signal in the core indicated hypoxia-mediated receptor downregulation as 
reported in previous studies for hypoxic 2D cultures [74, 75]. It should be noted that this 
absence of fluorescent signal in the center of large microtumor was not an artefact of staining 
(such as due to microtumor size-mediated diffusion limitation). Our previous study has shown 
uniform staining of other proteins such as E-cad throughout the core of the large microtumors 
[53].  
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Taken together, these observations offer mechanistic insights into tumor progression of ER+ 
microtumors as a function of microtumor size. This finding has high clinical significance, as we 
were able to induce loss of ER-α in large migratory microtumors in real time without affecting ER 
expression in small ones, both made of same non-invasive T47D cell line. Indeed, clinical 
studies have reported loss of ER-α, at both gene and protein level as the disease stage 
progresses from intraductal to invasive carcinomas [73]. About 30% of patients lose ER-α as the 
disease progresses to later stages [42]. Li and co-workers have demonstrated correlation 
between ER-α protein and tumor size as well as clinical stage in the patient samples. However, 
the lack of change in ER-α mRNA over time in both, large and small microtumors suggests that 
microtumor size does not influence the transcriptional level changes in ER-α. 
Cumulatively, these results suggest that ER-α receptor expression in large microtumors is 
affected by factors such as hypoxia and the loss of expression and establishes their similarity 
with invasive carcinomas. This similarity with clinical data further validates that the large 
microtumors (600 µm) show phenotypic traits of advanced stage breast tumors. Importantly, the 
microtumor models acquire such clinically relevant phenotypic characteristics in the same ER+ 
cell lines in a real time, without exposure to hypoxic chambers or genetic manipulations. 
 
3.5 Large T47D microtumors exhibit endocrine resistance to 4-OHT treatment. 
 
Our studies so far showed that the large microtumors recapitulate many characteristics of large 
microtumors with clinically advanced ER+ tumors such as pro-angiogenic behavior, 
mesenchymal marker upregulation, migratory behavior and more importantly, loss of ER in real 
time. We explored whether they also exhibited endocrine resistance, another feature of ER+ 
breast cancer progression [76]. A standard drug of choice in endocrine therapy, 4-
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hydroxytamoxifen (4-OHT) was used to treat the microtumors. The concentration of 4-OHT (50 
µM) was chosen based on the preliminary data from optimization studies that resulted in an 
effective inhibition in the growth of microtumors (data not shown). Briefly, both small and large 
microtumors were cultured in 1x1 cm2 PEGDMA devices for three days and treated with 50 µM 
4-OHT solution from day 3-6. On day 6, this solution was removed and the metabolic activity 
was analysed via alamarBlue® assay. 
A two-tailed t-test revealed that there were significant differences between growth of treated 
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microtumors based on size (t=31.65, df=15, p<0.0001).  
 The small (150 µm) microtumors treated with 4-OHT exhibited only 14% growth (86% inhibition) 
compared to that in the vehicle control group (Fig. 7A). In contrast, large microtumors treated 
with 4-OHT exhibited 65% growth (35% inhibition) of that observed in the vehicle controls. The 
data indicated that small microtumors were more sensitive to growth inhibition by 4-OHT than 
the larger ones.  
Additionally, we investigated whether the observed differences in the drug response are due to 
size-dependent diffusion limitations leading to the variable drug levels in small vs. large 
microtumor models. This was addressed by analysing the amount of 4-OHT post-treatment 
using mass spectrometry. The small and large microtumors treated with 4-OHT were harvested 
on day 6, followed by addition of Tris-KCl lysis buffer and homogenization. The lysates were run 
by a mass spectrometer to quantify 4-OHT levels in the microtumors. Results from the t-test 
summary showed p=0.4792, with t=0.7836 and degrees of freedom=3.801. This indicated that 
Figure 7: Large (600 µm) microtumors exhibit resistance to 4-OHT treatment. 
A) Small (150 µm) microtumors treated with 4-OHT exhibited only 14% of growth compared 
to their control while the large ones exhibited 65% of growth suggesting that large 
microtumors develop endocrine resistance (n=7 devices/group, * indicates p<0.05, unpaired 
t-test). B) Quantification of 4-OHT/microtumor through mass spectrometry revealed no 
significant size-dependent changes in 4-OHT levels in the small vs. large microtumors 
(p>0.05, n= 3 devices, unpaired t-test, NS: non-significant). C) ER-α immunofluorescence 
images of control and treated microtumors showed cytoplasmic presence of ER in the small 
microtumors after 4-OHT treatment (Row 2, region 2) as compared to controls (Row 2, 
region 1). While large microtumors did not reveal any such differences (Row 4, regions 4 and 
3). 
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there was no significant difference between total amount of 4-OHT/microtumor in small vs. large 
microtumors (p=0.4792; Fig. 7B). 
Further, to verify if the 4-OHT-induced growth inhibition in small microtumors was due to 
blockage and stabilization of receptor, immunofluorescence studies were performed on 4-OHT- 
treated microtumors. Previous studies have demonstrated that ligands such as 4-OHT that can 
conformationally block ER-α, hinder nuclear translocation and prevent downstream signaling 
involved in the cell proliferation [77, 78]. The results revealed that ER-α in most cells of 4-OHT-
treated small microtumor (150 μm) was not co-localized with nucleus but was localized in the 
cytoplasmic compartment (Fig. 7C highlighted area 2) as compared to untreated controls (Fig. 
7C highlighted area 1). However, we observed that overall large microtumors had no clear 
effect of 4-OHT treatment on ER-α receptor sub-cellular expression.  
Due to a significant difference in response to 4-OHT in the small vs. large microtumors, we can 
conclude that 4-OHT treatment is not as effective in inhibiting growth of large microtumors as in 
the small ones. One of the crucial mechanisms for observed endocrine resistance in large 
microtumors (600 µm) could be the loss of ER-α, which is the target of 4-OHT (Fig. 6B). It is 
obvious that as the drug target decreases from day 3 in large microtumors, the sensitivity to 
drug is bound to diminish. As highlighted by Osborne and Schiff [76], one of the most common 
explanations for endocrine resistance with ER+ breast cancer progression in clinic is loss of ER-
α. Therefore, these observations together indicate that the endocrine resistance in large 
microtumors may be due to the loss of the target ER-α from day 3 to day 6.  
It should be noted that the drug amount of 4-OHT per microtumor was not significantly different 
in small vs. large microtumors and may not have influenced the drug influence the response 
(Fig. 7A). However, it is important to consider that in an equal volume of cell lysates, the 
number of small microtumors (150 μm) is nearly 4- fold more than the large ones (600 μm) (data 
not shown). Thus, drug content normalized with respect to the number of microtumors showed 
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similar 4-OHT levels (Fig. 7B). When 4-OHT content was normalized to the total number of cells 
to determine amount of 4-OHT per cell, it was seen that large microtumors had significantly 
lower amount of drug compared to the smaller ones (data not shown). This indicated that 
although amount of 4-OHT/microtumor is not significantly different, either all cells in large 
microtumors had taken up less amount of drug or there was heterogeneity in the drug uptake 
throughout the large microtumor. Given that different regions within the microtumor experience 
varied physiological milieu, it might be worthwhile to investigate if certain region (periphery or 
core) preferentially take up the drug. Reduced drug uptake in large microtumors (600 µm) may 
be also be a cumulative effect of efflux pumps such as P-glycoprotein or multidrug resistance-
associated protein, upregulated in large microtumors that may result in lower amount of 
drug/cell and needs further investigation [79].  
 
3.6 Large T47D microtumors display unique trend in the growth factor receptor 
signalling. 
 
As large microtumors lose dependence on ER-α for survival and progression, we explored other 
proliferation pathways that could have contributed to their growth and aggressive phenotype. 
From literature, it is quite common to find dependence of clinically advanced stage tumors on 
the growth factor or receptor tyrosine kinase pathways such as Human Epidermal Growth 
Factor Receptor (EGFR/HER2) and Insulin Growth Factor Receptor (IGFR) [80]. Crosstalk with 
ER-α or independent activation of growth factor receptors could also lead to activation of 
downstream pathways that are frequently involved in breast tumor progression and metastasis 
clinically [81].  
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We investigated whether large microtumors were dependent on EGFR/HER2, widely reported 
pathway activated in ER+ advanced breast cancer [82]. We hypothesized that while small 
microtumors are dependent on ER-α for survival, large ones (600 µm) acquire growth factor 
receptor activation, which could further contribute to their migratory phenotype (Fig. 8A). Protein 
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analysis of upstream and downstream receptors of EGFR pathway was investigated in both, 
small and large microtumors. Western blotting indicated similar levels of phosphorylated EGFR 
(activated receptor form) at tyrosine residue, 845 in the small and large microtumors over 6 
days of culture (Fig. 8B). Interestingly, it was found that total EGFR levels decreased 
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significantly on day 3 and 6 in large microtumors, but not in the smaller ones. 
A two-way ANOVA was performed to test the effect of microtumor size and time (independent 
variables) on protein expression of microtumors. There was significant effect of time on 
pEGFR/EGFR expression (F [2, 12] =11.96 and p=0.0014) but not of microtumor size (F [1, 12] 
=3.137 and p=0.1019). However, there was significant interaction between microtumor size and 
time (F [2, 12] =6.184 and p=0.0143). For pAkt/Akt, there was significant effect of time (F [2, 12] 
=18.99 and p=0.0002) but not of microtumor size (F [1, 12] =0.09 and p=0.761). Also, there was 
no significant interaction between microtumor size and time (F [2, 12] =0.6228 and p=0.5529). 
For pERK/ERK, there was significant effect of time (F [2, 12] =14.56 and p=0.0006) but not of 
microtumor size (F [1, 12] =2.328 and p=0.153). In addition, there was no significant interaction 
between microtumor size and time (F [2, 12] =0.521 and p=0.6067). 
Overall, activation of EGFR pathway depicted by the ratio of p-EGFR/total EGFR levels 
suggests significant increase from day 3 to day 6 in large microtumors (Fig. 8C). This implies 
that even though p-EGFR levels were not microtumor size-dependent, the activation of EGFR 
pathway was affected by loss of total EGFR expression in large microtumors (600 µm) from day 
3 to day 6.  
Figure 8: Large microtumors display unique growth factor receptor signalling 
A) Schematic showing alternative proliferative pathways in the microtumor model. B) 
Western blotting for key molecules in growth factor receptor signalling shows higher levels of 
p-EGFR/Total EGFR in large microtumors. C) Densitometry analysis depicts significant 
upregulation of p-EGFR/total EGFR in large ones, whereas p-Akt/Akt or p-ERK/ERK was 
upregulated in both small and large microtumors in a time-dependent manner. They did not 
show significant effect of microtumor size. (n=3-5 experiments, * indicates p<0.05, two-way 
ANOVA). Note, white bars indicate small microtumors while black bars depict large ones.  
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In order to study if downstream effectors of EGFR pathway are also affected in microtumor size-
dependent manner, protein expression and phosphorylation of protein kinase B (Akt) and 
extracellular regulated kinase (ERK 1/2) were studied in these microtumors. As shown in Fig. 
8B, Akt was activated through increased levels of p-Akt/total Akt at serine 473 on days 3 and 6 
in both, small and large microtumors. Similarly, small and large microtumors had ERK 1/2 
activation (pERK 1/2/total ERK 1/2) at day 3 and 6 higher than day 1 (F [2, 12] =14.56, 
p=0.0006) due to increased levels of p-ERK 1/2 (Threonine 404/ Tyrosine 402). However, small 
microtumors (150 μm) had similar p-Akt/Akt and p-ERK 1/2/ ERK1/2 levels at day 3 and day 6 
as the large ones (Fig. 8C).  
The trend in EGFR expression of large (600 µm) microtumors is unlike many studies that report 
over-expression of EGFR in hypoxic tumors [83]. This observation needs to be investigated 
further. The downstream receptor analysis suggested that activation of these receptor kinase 
pathways are not dependent on microtumor size even though they show time-dependent 
changes. However, loss of EGFR suggests that the large microtumors could be using this 
pathway for adaptive mechanisms leading to aggressive behaviour and endocrine resistance 
[84].   
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4. CONCLUSIONS AND FUTURE DIRECTIONS 
 
We have developed in vitro size-controlled microtumor models that recapitulate important 
hallmarks of breast tumor progression such as hypoxic microenvironment, pro-angiogenic factor 
(Vegf) secretion, loss of ER-α, upregulation of mesenchymal makers without loss of epithelial 
cadherin (E-cad) and migratory phenotype just by controlling microtumor size in the same cell 
line. This model was well characterized for its ability to recapitulate early and advanced stage of 
the disease through upregulation of ROS, hypoxia and molecular markers (Hif-1α and Vegf) in 
the large microtumors in contrast to the small ones. In addition, hypoxia and oxidative stress-
induced damage was resulted in decrease in actively dividing population of cells in large 
microtumors (600 µm). Clinically observed feature such as collective cell migration further 
validated the utility of model for studying cancer biology and therapeutics. 
Further, the ER-α regulating proliferation in ER+ cells was downregulated in the large 
microtumors. Though no changes were observed in mRNA levels, large microtumors had 
decreased protein levels of ER-α over time unlike small ones. This loss in expression was linked 
to the hypoxia-mediated proteosomal degradation of ER. Additionally, large microtumors 
exhibited endocrine resistance to ER-targeted 4-OHT in contrast to small ones. Taken together, 
acquired mesenchymal phenotype, migratory phenotype, loss of ER-α, and endocrine 
resistance observed in large microtumors (600 µm) established the clinical relevance of these 
novel in vitro models due to their ability to recapitulate some of the clinical signatures of disease 
progression. On the other hand, small (150 µm) microtumors fabricated from the same non-
invasive cell line and minimal phenotypic changes serve as a 3D control of early stage, non-
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aggressive disease, making these models more powerful for interrogating biological 
mechanisms involved in tumor progression.   
Despite these studies, many mechanisms may exist that play an essential role in generating 
global phenomenon such as drug resistance and collective cell migration observed in the large 
microtumors. In order to study alternative growth pathways in large/aggressive tumors, status of 
growth factor receptor pathways was investigated. However, we observed that though upstream 
receptor (EGFR) was preferentially activated in large microtumors, downstream pathways such 
as Akt and ERK1/2 did not show any difference in the activation levels between small and large 
microtumors. Thus, future studies are required to delineate the mechanisms by which total 
EGFR protein levels are downregulated in large microtumors and alternative mechanisms that 
large microtumors utilize for showing aggressive traits and disease progression. Identification of 
these targets will enable efficient use of known inhibitors of these pathways and their 
combinations thereof to treat the aggressive tumors and demonstrate therapeutic benefit.  
In conclusion, recapitulation of growth-dependent changes in the physicochemical features of in 
vivo solid tumor microenvironment and acquisition of mesenchymal phenotype in the large 
microtumors were achieved using a single non-invasive T47D cell line. When cultured in non-
adhesive PEG hydrogel microwells, precise control over microtumor size enabled controlled 
changes in the microtumor microenvironment in a reproducible manner in both small and large 
microtumors. Such precise control over microenvironment further triggered underlying signaling 
mechanisms to capture phenotypic differentiation characteristic of early and late-stage disease 
in small (150 µm) and large (600 µm) microtumors, respectively just by changing the microtumor 
size alone and without any other artificial culture conditions. The use of the same cell line 
throughout these studies to mimic different stages of disease is of further importance.  
Taken together, one of the novel and significant findings of the studies presented in this thesis is 
that by manipulating tumor size (and size alone), we were able to produce 3D cultures that 
reflect different stages of tumor progression as revealed by different measures, all derived from 
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the same cells.  This demonstrates that size alone is sufficient to bring about this transformation 
of non-invasive cells to aggressive migratory phenotypes in 3D cultures. This is of further 
significance in various cancer studies mainly because it eliminates the need to use different cell 
lines to study tumors at different stages of disease.  
Therefore, these in vitro models are better than currently used approaches of gene 
manipulations, artificial culture conditions or use of different cell lines to represent the disease 
stage. These in vitro models can be used to screen drugs or develop better therapies in a stage-
specific manner unlike currently used cell culture models. However, these microtumor models 
also possess some limitations. Fabrication of polymeric moulds that generate arrays on 
hydrogels is a complicated procedure that requires expertise. In addition, many conventional 
cell-based assays optimized for 2D culture require further optimization for 3D culture to remove 
effects such as penetration limitation for the assay reagents. These models also lack 
extracellular matrix and stromal cells that are integral part of the in vivo tumor 
microenvironment. Nonetheless, the model is an advance over other models in several 
important ways such as uniformity and precise control over microtumor size, reproducibility, 
ability to capture tumor progression over a short duration of 6 days. All these advantages will 
easily allow incorporation of other microenvironmental factors to create more complex and 
realistic tumor microenvironments that exist in vivo.  
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APPENDIX A 
 
ABBREVIATIONS 
 
 
Term Abbreviation 
 
ECM   Extracellular Matrix 
ER-α   Estrogen Receptor alpha 
4-OHT  4-Hydroxytamoxifen 
EMT   Epithelial to Mesenchymal Transition 
VIM   Vimentin 
E-CAD  E-Cadherin 
Hif-1α   Hypoxia inducible factor 1 alpha 
ROS   Reactive oxygen species 
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